Viewing Study NCT00356109



Ignite Creation Date: 2024-05-05 @ 4:57 PM
Last Modification Date: 2024-10-26 @ 9:26 AM
Study NCT ID: NCT00356109
Status: COMPLETED
Last Update Posted: 2018-03-09
First Post: 2006-07-21

Brief Title: Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes
Sponsor: Eli Lilly and Company
Organization: Eli Lilly and Company

Study Overview

Official Title: A Phase 3 Open-Label Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus
Status: COMPLETED
Status Verified Date: 2018-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A study to test for non-inferiority of preprandial HIIP also known as AIR Inhaled Insulin PowderAIR is a registered trademark of AlkermesInc compared with preprandial injectable insulin insulin lispro with respect to HbA1c after 6 months of treatment in patients with type 1 diabetes mellitus

This study is designed also to examine insulin antibody levels in AIR Insulin -treated patients compared with injectable insulin-treated patients with type 1 diabetes

The present study is intended to determine if preprandial AIR Insulin is non-inferior to preprandial injectable insulin insulin lispro with respect to mean change in HbA1c from baseline to endpoint at 6 months in patients with type 1 diabetes
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
H7U-MC-IDAV None None None